Injection Pen Market Size, Share, and Trends 2025 to 2034

Injection Pen Market Size and Forecast 2025 to 2034

The global injection pen market size was estimated at USD 40.18 billion in 2024 and is anticipated to reach around USD 79.78 billion by 2034, expanding at a CAGR of 7.10% from 2025 to 2034. The remarkable features of injection pens including better dosing accuracy, increased patient acceptance, patient convenience and satisfaction, etc. accelerate the growth of the injection pen market. 

Injection Pen Market Key Takeaways

• North America led the global injection pen market with the largest market share of 43% in 2024.
• Asia Pacific is projected to grow at the fastest CAGR during the forecast period.
• By product type, the disposable segment dominated the global injection pen market in 2024.
• By product type, the reusable segment is projected to grow at a solid CAGR during the forecast period.
• By therapy, the diabetes segment dominated the global market in 2024.
• By therapy, the cancer segment is expanding at a significant CAGR during the forecast period.
• By end user, the homecare segment dominated the market in 2024.
• By end user, the hospitals and diagnostic centers segment is expected to be the fastest-growing during the forecast period. 

Role of Artificial Intelligence in the Injection Pen Market

The integration of artificial intelligence into injection devices plays a major role in the better assessment of fluctuations in blood glucose levels. AI also helps in the determination of changes in blood glucose levels caused by meals which allows for faster and more appropriate insulin response. AI minimizes patient efforts in assessing the right doses at the right time. AI helps patients with better self-administration and enhanced progressiveness. AI autoinjectors introduce additional cybersecurity. AI improves the functionality, enables real-time monitoring, and allows remote clinical trials, tailored medical treatments, and timely medical interventions.  AI-powered autoinjectors offer improved accuracy in delivering drugs and personalized treatments based on patient needs. 

U.S. Injection Pen Market Size and Growth 2025 to 2034

The U.S. injection pen market size was evaluated at USD 12.96 billion in 2024 and is predicted to be worth around USD 26.20 billion by 2034, rising at a CAGR of 7.29% from 2025 to 2034. 

North America led the global injection pen market with the largest market share of 43% in 2024. This is attributed to the increased prevalence of non-communicable diseases such as diabetes, cancer, cardiovascular diseases, and multiple sclerosis in the developed market like US and Canada. The increased prevalence of diabetes among the US population has boosted the adoption of injection pen. The increased health consciousness, higher healthcare expenditure, increased awareness regarding the innovative drug delivery devices, and easy availability of injection pens and its cartridges are the major factors that has augmented the growth of the North America injection pen market.

In North America, better knowledge of modern drug delivery methods, and easy access to injection pens and cartridges drive the market’s growth in this region. In the U.S., the government laws are supporting the healthcare system. There is an annual increase in the number of patients with chronic conditions in this region.

Asia Pacific is projected to grow at the fastest CAGR during the forecast period.The growing prevalence of various chronic diseases among the population owing to the unhealthy food habits, physical inactivity, and increasing consumption of alcohol and tobacco among the youth population. Most of the deaths due to the chronic diseases are recorded in the low and middle income countries, which offers the huge growth potential to the market players in Asia Pacific region.

The expanding urbanization, the growing aged population, and the changing lifestyles of people accelerate the market’s growth in the Asia Pacific region. The need for injection pens boosted remarkably due to their uses for insulin self-administration and other necessary medications to treat chronic conditions. In China, the demographic shift and the changing lifestyles of people will drive the market’s expansion.

Market Overview

The injection pen refers to a medical device used by patients with chronic conditions like diabetes to prefer dose adjustments and multiple injections based on individual needs. The growing number of cases like osteoporosis, multiple sclerosis, etc. are driving the demand for injection pens in the market. The huge adoption of innovative reusable injection pens and the growing preference for automotive injection pens accelerate the growth of the injection pen market. The benefits of automated injection pens to medical practitioners include safety, convenience, simplicity, and accuracy in medication administration. Moreover, the growing number of diabetic patients in the world need insulin injections. According to the National Institute of Health, the sales of injection pens reached success due to their increasing need to administer insulin in type 2 diabetes patients. These medical devices replaced syringes which are tedious to use while injection pens offer simplicity to patients. 

Injection Pen Market Growth Factors

• There are several factors such as the growing prevalence of chronic diseases, technological advancements in drug delivery devices, rising investments in research and clinical trials, rising number of government approvals, and favorable reimbursement policies are significantly driving the growth of the global injection pen market.
• The inconveniences associated with the traditional syringes are the prominent factors that are shifting the consumer preference towards the advanced injection pens.
• The growing investments by pharmaceutical manufacturers in the development of new drugs are fueling its demand among consumers, which in turn is boosting the demand for injection pens for efficiently administering drugs. 
• The growing healthcare expenditure and rising awareness regarding the availability of innovative injection pens are spurring the growth of the global injection pen market.
• The conveniences associated with the injection pens allow the patients to self-administer drugs without the need for any professional assistance, which also reduces the cost. 
• Hence, injection pens are gaining rapid traction among patients who frequently require to administer drugs.
• The rising burden of chronic diseases such as cancer, diabetes, autoimmune diseases, and cardiovascular diseases is exponentially contributing to the growth of the injection pen market.
• According to the International Diabetes Federation, currently around 537 million people are living with diabetes and this number is expected to reach 783 million by 2045.
• According to the World Health Organization, diabetes is a major cause of kidney failure, blindness, and stroke. Moreover, cardiovascular diseases account for 32% of the global deaths and it is the leading cause of death across the globe. Therefore, the growing prevalence of various chronic and non-communicable diseases among the global population is expected to spur the demand for the injection pen market across the globe.

Market Scope

Market Dynamics 

Driver

The frequent dosing of medications required for chronic conditions drives the market’s growth. These devices enable patients to manage their time and location which offers comfort in their homes, workplaces, and social routines. They offer financial advantages to patients and the healthcare system by reducing the need for frequent visits to hospitals or clinics. The growing focus of healthcare industries on environmental sustainability boosts the market’s expansion by preferring reusable injection pens which are an environment-friendly approach.  

Restraint

If companies do not follow the prescribed standards and the specific provisions of regulatory bodies like the U.S. FDA, they can face regulatory issues in their industrial operations. Companies need to comply with biocompatibility testing and rigorous testing. A lack of education and training about the usage of new injection devices can lead to errors and affect the safety of patients and healthcare providers. 

Opportunity

The increased focus on patient-centric device design and connected devices will uplift the market’s growth. The connected devices will improve treatment outcomes and the user experience. The companies focus on resolving patient concerns like needle phobia and pain by introducing features like easier injections and finer needles. In May 2024, Novo Nordisk decided to use its Flextouch pen for injection of the weight loss drug in the U.S. like its use in the rest of the world.  

Product Type Insights

The disposable segment dominated the global injection pen market in 2024. This is attributed to the safety and affordability associated with the disposable injection pens. The disposable injection pens can be used only once and it promotes the safety against the blood-borne diseases that occurs through the reusability of the injections. The easy availability, increased consumer awareness, rising healthcare expenditure, and rising prevalence of insulin related diseases has fostered the growth of the disposable injection pen segment in the past few years.

The reusable segment is projected to grow at a solid CAGR during the forecast period. This can be attributed to the long life cycle of the reusable pens. The frequent users of the injection pens acquires the reusable injection pens once and it lasts for several years. This facilitates convenience to the patients. This growing awareness regarding the benefits of the reusable injection pens among the patients is expected to foster the growth of this segment in the forthcoming years.

Therapy Insights

The diabetes segment dominated the global market in 2024. The unhealthy food habits results in the increasing blood glucose levels. It is a major cause of type 1 diabetes. When the body becomes resistant to insulin, it results in the occurrence of type 2 diabetes. The rising prevalence of type 1 and type 2 diabetes among the global population is fueling the growth of this segment.

The cancer segment is expanding at a significant CAGR during the forecast period. This rising cases of cancer owing to rising prevalence of smoking, growing alcohol and tobacco consumption, rising consumption of processed food, and various other factors, the number of cancer cases is expected to grow rapidly. According to the International Agency for Research on Cancer, the global cancer cases are estimated to grow by 47% from 2020 to 2040. It is expected that 28.4 million cases will be recorded in 2040, globally. The lungs cancer, breast cancer, and prostate cancer are the most prominent cancer types across the globe.

End User Insights

By end user, the hospitals and diagnostic centers segment is expected to be the fastest-growing in the injection pen market during the forecast period. This segmental growth is expected due to the noticeable government efforts and the huge acceptance of hospitals and diagnostic centers by people. The government is trying to enhance healthcare infrastructure and the diabetes patient population is increasing. The enhanced healthcare expenditure by consumers, higher disposable income, and the growing consumer awareness about injection pen usage are accelerating the growth of this segment in the market. The presence of specific infrastructure and advanced medical equipment in hospitals boosts the demand and need for these healthcare facilities. A large number of diabetes patients and people with chronic conditions need injection pens and different tests performed in hospitals. The growing number of elderly population and the rising incidence of diseases like diabetes, etc. propel this segmental growth.

Injection Pen Market Companies

• Eli Lilly
• Novo Nordisk
• Sanofi
• Merck
• AstraZeneca
• Ypsomed
• F.Hoffman-La Roche
• Becton Dickinson and Company
• Novartis
• Pfizer
• Haselmeier
• Owen Mumford
• WOCKHARDT
• Companion Medical

Recent Developments

• In May 2024, Eisai Co. and Nippon medac Co. announced the launch of a Metoject subcutaneous injection pen in Japan for treating rheumatic arthritis. 
• In February 2024, the anti-rheumatic agent product of Eisai Co. and Nippon medac Co. received manufacturing and marketing approval and it was published in the National Health Insurance Drug Price List of Japan.  

Segments Covered in the Report

By Product Type

• Reusable
• Disposable

By Therapy

• Diabetes
• Cancer
• Osteoporosis
• Autoimmune Diseases
• Growth Hormone Therapy
• Multiple Sclerosis
• Fertility
• Cardiovascular Diseases
• Others

By End User

• Hospitals & Diagnostic Centers
• Homecare

By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa